# BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)

> clinical trial · VERIFIED · 2026-08-07

Status: NOT_YET_RECRUITING · Sponsor: Institute of Hematology & Blood Diseases Hospital, China · Condition: AL Amyloidosis

- Company: Institute of Hematology & Blood Diseases Hospital, China
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT07751471

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.